The global neglected tropical diseases diagnosis market size was estimated at USD 5.3 billion in 2016. Formal recognition of Neglected Tropical Diseases (NTDs) in the sustainable development goals as a global target is expected to drive market growth. In the past, NTDs did not receive the level of attention and resources that diseases such as HIV and malaria received. However, they are now gaining significant attention from healthcare organizations, which is anticipated to increase funding for R&D of diagnostic methods and treatment options.
Increase in programs to tackle NTDs is expected to directly impact the growth of this market. There is a growing demand for highly sensitive and rapid diagnostic tests to fulfill unmet needs. Diagnostics are vital for treatment planning, but there is still a gap between clinical diagnosis and treatment of NTDs. This hints at the growing need for relevant diagnostic tests.
Furthermore, the market is expected to benefit from active participation of international health organizations, such as PATH, for accelerating the development as well as implementation of robust diagnostic methods for these diseases. These organizations have formed strategic alliances with other entities to develop and commercialize novel detection assays in order to drive efforts targeting NTDs. In February 2015, WHO called on developing countries to invest USD 1 per person annually until 2030 to tackle 17 NTDs. Such initiatives to enhance patient outcomes are anticipated to impel market growth.
Dengue dominated the market in 2016 and is expected to maintain its position throughout the forecast period. This dominant share can be attributed to continuous efforts undertaken by healthcare companies and institutes to develop and commercialize enhanced and less complicated disease diagnostic platforms. For example, in November 2014, a research study was conducted to evaluate the effectiveness of dengue NS1 antigen rapid tests and ELISA kits from several companies, such as Bio-Rad and Alere, for early diagnosis.
As per WHO updates in April 2017, the global incidence of dengue has increased substantially in recent decades, and it is documented that half of the world’s population is at risk of acquiring the disease. Although there are a large number of diagnostic kits available for dengue virus detection, this segment still offers many opportunities for growth.
Factors taken into consideration while opting for various diagnostic methods include specificity, sensitivity, and cost-effectiveness as well as availability of skilled personnel. Conventional diagnostic methods are based on macroscopic and microscopic identification of pathogens through gram stain, pathogen culturing, biochemical methods, and serology tests.
Relatively greater availability of conventional methods, compared to modern techniques, across a large number of labs and clinics is a key factor that has enabled this segment’s dominance in the market. However, these tests have certain limitations pertaining to speed, timeline, and accuracy. Furthermore, rapid technological advances are compelling end users to opt for molecular/modern methods over conventional methods.
Modern diagnostic methods are designed to overcome limitations of specificity and accuracy. The various advantages of modern assays have augmented their scope of application, such as outpatient monitoring, large screening programs in developing regions, and point-of-care testing (POCT). This is expected to serve as a high impact-rendering driver.
A substantial number of studies have been conducted for comparative analysis of centralized and point-of-care (POC) services, a factor that has positively impacted the growth of both segments. Centralized testing services accounted for a major share in the market due to the local presence of a large number of facilities across the world. Moreover, currently, the number of centralized service centers is significantly higher than that of POC centers.
On the other hand, the POC service segment is expected to grow at a lucrative rate throughout the forecast period. Various advantages of POCT devices, such as portability and easy usage, are expected to bolster its adoption. Furthermore, these services offer quick results, allowing immediate treatment or intervention and consequently, better patient outcomes. Recently, the U.S. FDA granted the “Chagas Detect Plus Rapid Test Kit” a 510K clearance. This POCT for Chagas disease has been developed by InBios International. Such achievements are expected to significantly impact the growth of this segment throughout the forecast period.
NTD diagnostic devices find application in various healthcare settings, such as hospitals, private practices, laboratories, and homecare. Rapid advancements in diagnostic kits and high disease burden will result in rising application of these devices in the coming years.
Clinical laboratories emerged as the dominant end-use segment in the neglected tropical diseases diagnosis market in 2016. This can be attributed to the presence of a substantial number of laboratories across the globe. This segment is also anticipated to expand at a steady CAGR in the coming years owing to rise in the number of skilled personnel in labs.
The home healthcare segment is expected to grow at a lucrative rate over the forecast period. This growth is anticipated to be supported by increased adoption of POCT services. Moreover, a major benefit offered by this segment is improved access to healthcare in remote and rural areas, which in turn, will spur segment growth.
NTDs are endemic to almost 150 countries and have affected people across the globe. The burden of this disease is mostly concentrated in tropical and subtropical countries in Africa, Asia, and Latin America. The market in Latin America is expected to grow at a significant pace. Untapped potential and increasing awareness among the population in Latin America countries regarding ways of tackling NTDs are expected to accelerate the growth of this regional market.
Taking into account disease prevalence, diagnostics availability, access to assays, and presence of target population, Asia Pacific accounted for the dominant share in 2016. The regional market is expected to retain its position throughout the forecast period owing to constantly improving healthcare infrastructure in Asian countries such as India and China. Continuous growth in GDP, high prevalence of neglected tropical diseases in the region, and the presence of a large target population will also continue to support the growth of this market.
F. Hoffmann-La Roche Ltd.; Abbott; Thermo Fisher Scientific, Inc.; ZeptoMetrix; InBios International, Inc.; Genome Diagnostics Pvt. Ltd; Omega Diagnostics Group PLC; Coris Bioconcept SPRL; DiaSys Diagnostic Systems GmbH; and Oscar Medicare Pvt Ltd. are some of the prominent players in the market.
These players are undertaking various strategic initiatives to increase their share in the market. New product development, collaborations, and partnerships are some such endeavors. Recently, Abbott completed the acquisition of Alere, a move that is expected to enhance the former company’s share in the market.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million and CAGR from 2017 to 2025
Asia Pacific, Latin America, Middle East & Africa Europe, North America
India, China, Indonesia, Malaysia, Brazil, Venezuela, Colombia, Nigeria, Germany, U.K., U.S., Canada
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5-analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global neglected tropical diseases diagnosis market report on the basis of disease, diagnostic method, end use, service type, and region:
Disease Outlook (Revenue, USD Million, 2014 - 2025)
Chagas Disease (American Trypanosomiasis)
Soil-transmitted Helminth Infections
Scabies and Other Ectoparasites
Diagnostic Method Outlook (Revenue, USD Million, 2014 - 2025)
Service Type Outlook (Revenue, USD Million, 2014 - 2025)
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East & Africa
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.